Fig. 1From: Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims databasePatient selection. TEIC Teicoplanin, UDCA ursodeoxycholic acid, GL glycyrrhizin. *A specific drug refers to a drug for which a claim can be made for treatment and management fee for specific drugs, and based on the drug whose blood levels are assumed to be clinically measured (Additional file 1)Back to article page